Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Asset Writedowns and Impairment (2023 - 2025)

Ptc Therapeutics has reported Asset Writedowns and Impairment over the past 3 years, most recently at $500000.0 for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at $500000.0 for Q4 2025, down 99.69% from a year ago — trailing twelve months through Dec 2025 was $160.5 million (changed 0.31% YoY), and the annual figure for FY2025 was $1.0 million, down 75.58%.
  • Asset Writedowns and Impairment for Q4 2025 was $500000.0 at Ptc Therapeutics, up from $400000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for PTCT hit a ceiling of $217.8 million in Q2 2023 and a floor of $100000.0 in Q2 2025.
  • Median Asset Writedowns and Impairment over the past 3 years was $500000.0 (2025), compared with a mean of $54.3 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: crashed 99.91% in 2024 and later crashed 50.0% in 2025.
  • Ptc Therapeutics' Asset Writedowns and Impairment stood at $217.8 million in 2023, then fell by 26.77% to $159.5 million in 2024, then crashed by 99.69% to $500000.0 in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $500000.0 (Q4 2025), $400000.0 (Q3 2025), and $100000.0 (Q2 2025) per Business Quant data.